References
- Sato T, Han F, Yamamoto A. The biology and management of uveal melanoma. Curr Oncol Rep 2008;10:431–8.
- Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 2010;363:711–23.
- Khan SA, Callahan MK, Postow M, Chapman P, Schwartz G, Dickson M, et al. Ipilimumab in the treatement of uveal melanoma: The Memorial Sloan-Kettering Cancer Center experience. Abstract #8549, ASCO Annual Meeting. 2012.
- Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: Safety and clinical efficacy. Cancer Immunol Immunother 2012;61:41–8.
- Maio M, Sileni VC, Pilla L, Nicoletti SVL, Di Guardo L, Queirolo P, et al. Efficacy and safety of ipilimumab in patients with pretreated, ocular melanoma: Experience from Italian clinics participating in the European Expanded Access Programme. Abstract #1133P, ESMO Annual Meeting. 2012.
- Lawrence D, McDermott D, Hamid O, Weber J, Wolchok J, Richard J, et al. Treatment of patients (pts) with stage III or IV melanoma on an ipilimumab (Ipi) expanded access program (EAP): Results for 3mg/kg cohort. Poster, SMR meeting. 2012.
- Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study. Ann Surg Oncol 2005;12:1005–16.
- Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl J Med 2011;364:2517–26.